Sucrose, fructose, glucose, and their link to metabolic syndrome and cancer

Nutrition

Volumn 31, Issue 1, 2015, Pages 249-257

  Das, Undurti N ^a  

^a UND Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL FATTY ACID; FRUCTOSE; GLUCOSE; SUCROSE; CARBOHYDRATE DIET; FAT INTAKE; PROTEIN INTAKE;

BODY MASS; CALORIC INTAKE; CARBOHYDRATE ANALYSIS; CARBOHYDRATE DIET; CARBOHYDRATE INTAKE; CARBOHYDRATE METABOLISM; EDITORIAL; ENERGY CONSUMPTION; EXERCISE; FAT INTAKE; FATTY ACID METABOLISM; HUMAN; INCIDENCE; INFLAMMATION; LIPID DIET; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; SEDENTARY LIFESTYLE; SOFT DRINK; ADMINISTRATION AND DOSAGE; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PROTEIN INTAKE; YOUNG ADULT;

ADULT; AGED; DIETARY CARBOHYDRATES; DIETARY FATS; DIETARY PROTEINS; ENERGY INTAKE; FEMALE; FRUCTOSE; GLUCOSE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS; SUCROSE; YOUNG ADULT;

EID: 84922210663     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.05.015     Document Type: Editorial

References (87)

1. National Health and Nutrition Examination Survey. Accessed July 17, 2014 from. http://www.cdc.gov/nchs/nhanes.htm.
2. Dietary reference intakes: guiding principles for nutrition labeling and fortification 2004, National Academies Press, Washington DC.
3. U.S. Department of Agriculture. Sugar: world markets and trade 2013, U.S. Department of Agriculture, Washington DC.
4. Hyvonen L., Koivistoinen P. Fructose in food systems. Nutritive sweeteners 1982, 133-144. Applied Science Publishers, London. G.G. Birch, K.J. Parker (Eds.).
5. Wach W. Fructose. In: Ullmann's Encyclopedia of Industrial Chemistry 2004, Wiley-VCH, Weinheim.
6. McWilliams M. Foods: experimental perspectives 2000, Prentice Hall, Upper Saddle River, New Jersey. 2nd ed.
7. Dills W.L. Protein fructosylation: fructose and the Maillard reaction. Am J Clin Nutr 1993, 58:779 S-787 S.
8. Hanover L.M., White J.S. Manufacturing, composition, and application of fructose. Am J Clin Nutr 1993, 58:724 S-732 S.
9. Kretchmer N., Hollenbeck C.B. Sugars and sweeteners 1991, CRC Press, Inc., Boca Raton, FL.
10. Guthrie F.J., Morton F.J. Food sources of added sweeteners in the diets of Americans. J Am Dietetic Assoc 2000, 100:43-51.
11. Bachman J.L., Reedy J., Subar A.F., Krebs-Smith S.M. Sources of food group intakes among the US population, 2001 to 2002. J Am Diet Assoc 2008, 108:804-814.
12. Heinz F., Lamprecht W., Kirsch J. Enzymes of fructose metabolism in human liver. J Clin Invest 1968, 47:1826-1832.
13. Brown J., Miller D.M., Holloway M.T., Leve G.D. Hexokinase enzymes in liver and adipose tissue of man and dog. Science 1967, 155:205-207.
14. Underwood A.H., Newsholme E.A. Some properties of phosphofructokinase from kidney cortex and their relation to glucose metabolism. Biochem J 1967, 104:296-299.
15. Beitner R., Haberman S., Livni L. Complementarity in the regulation of phosphoglucomutase, phosphofructokinase and hexokinase; the role of glucose 1,6-bisphosphate. Biochim Biophys Acta 1975, 397:355-369.
16. Colombo G., Tate P.W., Girotti A.W., Kemp R.G. Interaction of inhibitors with muscle phosphofructokinase. J Biol Chem 1975, 250:9404-9412.
17. Probst I., Quentmeier A., Schweickhardt C., Unthan-Fechner K. Stimulation by insulin of glycolysis in cultured hepatocytes is attenuated by extracellular ATP and puromycin through purine-dependent inhibition of phosphofructokinase 2 activation. Eur J Biochem 1989, 182:387-393.
18. Collison K.S., Saleh S.M., Bakheet R.H., Al-Rabiah R.K., Inglis A.L., Makhoul N.J., et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity 2009, 17:2003-2013.
19. Parks E.J., Skokan L.E., Timlin M.T., Dingfelder C.S. Dietary sugars stimulate fatty acid synthesis in adults. J Nutr 2008, 138:1039-1046.
20. Chong M.F., Fielding B.A., Frayn K.N. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr 2007, 85:1511-1520.
21. Wiebe N., Padwal R., Field C., Marks S., Jacobs R., Tonelli M. A systematic review on the effect of sweeteners on glycemic response and clinically relevant outcomes. BMC Med 2011, 9:123.
22. Tappy L., Lê K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010, 90:23-46.
23. Basaranoglu M., Basaranoglu G., Sabuncu T., Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013, 19:1166-1172.
24. Dowman J.K., Hopkins L.J., Reynolds G.M., Nikolaou N., Armstrong M.J., Shaw J.C., et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 2014, 184:1550-1561.
25. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., et al. A pharmacologic map of the PI3-K family defines a role for p110 alpha in insulin signaling. Cell 2006, 125:733-747.
26. Kalaany N.Y., Sabatini D.M. Tumours with PI3 K activation are resistant to dietary restriction. Nature 2009, 458:725-731.
27. Whitman M., Kaplan D.R., Schaffhausen B., Cantley L., Roberts T.M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985, 315:239-242.
28. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. Signaling through phosphoinositide 3-kinases: the lipids take centre stage. Current Opinion Cell Biol 1999, 11:219-225.
29. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013, 17:675-699.
30. Chalhoub N., Baker S.J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150.
31. Ruderman N.B., Kapeller R., White M.F., Cantley L.C. Activation of phosphoinositide kinase by insulin. Proc Natl Acad Sci U S A 1990, 87:1411-1415.
32. Taniguchi C.M., Kondo T., Sajan M., Luo J., Bronson R., Asano T., et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 2006, 3:343-353.
33. Cordero-Espinoza L., Hagen T. Increased concentrations of fructose 2,6-bisphosphate contribute to the Warburg effect in phosphatase and tensin homolog (PTEN)-deficient cells. J Biol Chem 2013, 288:36020-36028.
34. Mack D.O., Watson J.J., Johnson B.C. Effect of dietary fat and sucrose on the activities of several rat hepatic enzymes and their diurnal response to a meal. J Nutr 1975, 105:701-713.
35. Fitch W.M., Chaikoff I.L. Extent and patterns of adaptations of enzyme activities in livers of normal rats fed diets high in glucose and fructose. JBiol Chem 1960, 235:554-557.
36. Briata P., Laurino C., Gherzi R. c-myc gene expression in human cells is controlled by glucose. Biochem Biophys Res Commun 1989, 165:1123-1129.
37. Liu H., Huang D., McArthur D.L., Boros L.G., Nissen N., Heaney A.P. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res 2010, 70:6368-6376.
38. Mapungwana S.M., Davies D.P. The effect of fructose on pyruvate kinase activity in isolated hepatocytes. Biochem J 1982, 208:171-178.
39. Israelsen W.J., Dayton T.L., Davidson S.M., Fiske B.P., Hosios A.M., Bellinger G., et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013, 155:397-409.
40. Das U.N. Is obesity an inflammatory condition?. Nutrition 2001, 17:953-966.
41. Das U.N. Obesity, metabolic syndrome X, and inflammation. Nutrition 2002, 18:430-432.
42. Pfeiffer A., Janott J., Möhlig M., Ristow M., Rochlitz H., Busch K., et al. Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 1997, 29:111-114.
43. Makino N., Maeda T., Sugano M., Satoh S., Watanabe R., Abe N. High serum TNF-alpha level in type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications 2005, 19:347-355.
44. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415.
45. Lechleitner M., Herold M., Dzien-Bischinger C., Hoppichler F., Dzien A. Tumour necrosis factor-alpha plasma levels in elderly patients with Type 2 diabetes mellitus-observations over 2 y. Diabet Med 2002, 19:949-953.
46. Das U.N. Is metabolic syndrome X an inflammatory condition?. Exp Biol Med 2002, 227:989-997.
47. Ramos E.J.B., Xu Y., Romanova I., Chen C., Quinn R., Inui A., et al. Is obesity an inflammatory disease?. Surgery 2003, 134:329-335.
48. Das U.N. Metabolic syndrome is a low-grade systemic inflammatory condition. Expert Rev Endocrinol Metab 2010, 4:577-592.
49. Benetti E., Mastrocola R., Rogazzo M., Chiazza F., Aragno M., Fantozzi R., et al. High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR-γ agonism. Mediators Inflamm 2013, 2013:509502.
50. Liu X., Xue Y., Liu C., Lou Q., Wang J., Yanagita T., et al. Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice. Lipids Health Dis 2013, 12:109.
51. Hsieh F.C., Lee C.L., Chai C.Y., Chen W.T., Lu Y.C., Wu C.S. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutr Metab 2013, 10:35.
52. Veličković N., Djordjevic A., Vasiljević A., Bursać B., Milutinović D.V., Matić G. Tissue-specific regulation of inflammation by macrophage migration inhibitory factor and glucocorticoids in fructose-fed Wistar rats. Br J Nutr 2013, 110:456-465.
53. Pan Y., Wang Y., Cai L., Cai Y., Hu J., Yu C., et al. Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br J Pharmacol 2012, 166:1169-1182.
54. Pan Y., Zhu G., Wang Y., Cai L., Cai Y., Hu J., et al. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 2013, 24:146-155.
55. Hayashi T., Juliet P.A., Miyazaki A., Ignarro L.J., Iguchi A. High glucose downregulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implications for atherosclerosis. Biochim Biophys Acta 2007, 1772:364-372.
56. Häberer D., Thibault L., Langhans W., Geary N. Beneficial effects on glucose metabolism of chronic feeding of isomaltulose versus sucrose in rats. Ann Nutr Metab 2009, 54:75-82.
57. 5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukotrienes Essen Fatty Acids 2005, 72:343-350.
58. Jones D.B., Carter R.D., Mann J.I. Indirect evidence of impairment of platelet desaturase enzymes in diabetes mellitus. Horm Metab Res 1986, 18:341-344.
59. Rodríguez Y., Christophe A.B. Long-chain omega6 polyunsaturated fatty acids in erythrocyte phospholipids are associated with insulin resistance in non-obese type 2 diabetics. Clin Chim Acta 2005, 354:195-199.
60. Kröger J., Zietemann V., Enzenbach C., Weikert C., Jansen E.H., Döring F., et al. Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2011, 93:127-142.
61. 5 desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot Essen Fatty Acids 2007, 76:251-268.
62. Sergeant S., Hugenschmidt C.E., Rudock M.E., Ziegler J.T., Ivester P., Ainsworth H.C., et al. Differences in arachidonic acid levels and fatty acid desaturase (FADS) gene variants in African Americans and European Americans with diabetes or the metabolic syndrome. Br J Nutr 2012, 107:547-555.
63. 5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians. Lipid Health Dis 2010, 9:130.
64. Suresh Y., Das U.N. Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus. Prostaglandins Leukot Essen Fatty Acids 2001, 64:37-52.
65. Suresh Y., Das U.N. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: Effect of ω-6 fatty acids. Nutrition 2003, 19:93-114.
66. Suresh Y., Das U.N. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: Effect of ω-3 fatty acids. Nutrition 2003, 19:213-228.
67. 4 as possible antidiabetic molecules. Prostaglandins Leukot Essen Fatty Acids 2013, 88:201-210.
68. Das U.N. Lipoxins, resolvins, protectins, maresins and nitrolipids and their clinical implications with specific reference to diabetes mellitus and other diseases: part II. Clin Lipidol 2013, 8:465-480.
69. Das U.N. Metabolic syndrome pathophysiology: the role of essential fatty acids and their metabolites 2010, Wiley-Blackwell Publishers, Ames, IA.
70. Das U.N. Molecular basis of health and disease 2011, Springer, New York.
71. White P.J., St-Pierre P., Charbonneau A., Mitchell P.L., St-Amand E., Marcotte B., et al. Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis. Nat Med 2014, 20:664-669.
72. White P.J., Arita M., Taguchi R., Kang J.X., Marette A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010, 59:3066-3073.
73. Gonzalez-Periz A., Horrillo R., Ferre N., Gronert K., Dong B., Morán-Salvador E., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23:1946-1957.
74. Wei S., Li J., Shen M., Jia W., Chen N., Chen T., et al. Cellular production of n-3 PUFAs and reduction of n-6-n-3 ratios in the pancreatic β-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes 2010, 59:471-478.
75. Bellenger J., Bellenger S., Bataille A., Massey K.A., Nicolaou A., Rialland M., et al. High pancreatic n-3 fatty acids prevent STZ induced diabetes in fat-1 mice: Inflammatory pathway inhibition. Diabetes 2011, 60:1090-1099.
76. Hellman J., Tang Y., Kosuri M., Bhatnagar A., Spite M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 2011, 25:2399-2407.
77. Robbez Masson V., Lucas A., Gueugneau A.M., Macaire J.P., Paul J.L., Grynberg A., et al. Long-chain (n-3) polyunsaturated fatty acids prevent metabolic and vascular disorders in fructose-fed rats. J Nutr 2008, 138:1915-1922.
78. Zák A., Tvrzická E., Vecka M., Jáchymová M., Duffková L., Stanková B., et al. Severity of metabolic syndrome unfavorably influences oxidative stress and fatty acid metabolism in men. Tohoku J Exp Med 2007, 212:359-371.
79. Corpeleijn E., Feskens E.J., Jansen E.H., Mensink M., Saris W.H., de Bruin T.W., et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 2006, 49:2392-2401.
80. Wang Y., Botolin D., Xu J., Christian B., Mitchell E., Jayaprakasam B., et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res 2006, 47:2028-2041.
81. Brenner R.R., Rimoldi O.J., Lombardo Y.B., González M.S., Bernasconi A.M., Chicco A., et al. Desaturase activities in rat model of insulin resistance induced by a sucrose-rich diet. Lipids 2003, 38:733-742.
82. Prasad M.R., Joshi V.C. Regulation of rat hepatic stearoyl coenzyme A desaturase. The roles of insulin and carbohydrate. J Biol Chem 1979, 254:997-999.
83. Brenner R.R. Regulatory function of delta6 desaturate-key enzyme of polyunsaturated fatty acid synthesis. Adv Exp Med Biol 1977, 83:85-101.
84. Das U.N. Essential fatty acids-a review. Current Pharmaceut Biotech 2006, 7:467-482.
85. Das U.N. Essential fatty acids: biochemistry, physiology, and pathology. Biotechnology J 2006, 1:420-439.
86. Mayer K., Schmidt R., Muhly-Reinholz M., Bogeholz T., Gokorsch S., Grimminger F., et al. Invitro mimicry of essential fatty acid deficiency in human endothelial cells by TNFα impact of ω-3 versus ω-6 fatty acids. J Lipid Res 2002, 43:944-951.
87. Kelishadi R., Mansourian M., Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: A systematic review and meta-analysis. Nutrition 2014, 30:503-510.